Asset profile
Opdivo Qvantig
Monoclonal antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
83 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Opdivo Qvantig: this drug | Approved | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 |
…and 68 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
6 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.